Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Targeting the epidermal growth factor receptor in solid tumor malignancies.

Nedergaard MK, Hedegaard CJ, Poulsen HS.

BioDrugs. 2012 Apr 1;26(2):83-99. doi: 10.2165/11599760-000000000-00000. Review.

PMID:
22385404
[PubMed - indexed for MEDLINE]
2.

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S.

Int J Cancer. 2003 Jun 10;105(2):273-80.

PMID:
12673691
[PubMed - indexed for MEDLINE]
3.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

Dassonville O, Bozec A, Fischel JL, Milano G.

Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. Epub 2007 Feb 26. Review.

PMID:
17324578
[PubMed - indexed for MEDLINE]
4.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
[PubMed - indexed for MEDLINE]
5.

Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting.

Omidfar K, Shirvani Z.

DNA Cell Biol. 2012 Jun;31(6):1015-26. doi: 10.1089/dna.2011.1529. Epub 2012 Jan 25. Review.

PMID:
22277093
[PubMed - indexed for MEDLINE]
6.

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M.

Clin Cancer Res. 2006 Aug 1;12(15):4671-7.

PMID:
16899617
[PubMed - indexed for MEDLINE]
Free Article
7.

Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.

Yewale C, Baradia D, Vhora I, Patil S, Misra A.

Biomaterials. 2013 Nov;34(34):8690-707. doi: 10.1016/j.biomaterials.2013.07.100. Epub 2013 Aug 13. Review.

PMID:
23953842
[PubMed - indexed for MEDLINE]
8.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.

PMID:
21531084
[PubMed - indexed for MEDLINE]
9.

Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.

Kuo T, Fisher GA.

Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S62-70. Review.

PMID:
16336751
[PubMed - indexed for MEDLINE]
10.

Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

Mamot C, Rochlitz C.

Swiss Med Wkly. 2006 Jan 7;136(1-2):4-12. Review.

PMID:
16597093
[PubMed - indexed for MEDLINE]
11.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
[PubMed - indexed for MEDLINE]
12.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

PMID:
16951222
[PubMed - indexed for MEDLINE]
Free Article
13.

Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.

Miyamoto S, Fukami T, Yagi H, Kuroki M, Yotsumoto F.

Anticancer Res. 2009 Mar;29(3):823-30. Review.

PMID:
19414315
[PubMed - indexed for MEDLINE]
Free Article
14.

Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.

Okamoto I.

FEBS J. 2010 Jan;277(2):309-15. doi: 10.1111/j.1742-4658.2009.07449.x. Epub 2009 Nov 18. Review.

PMID:
19922468
[PubMed - indexed for MEDLINE]
15.

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW.

Cancer Res. 2003 Jun 15;63(12):3154-61.

PMID:
12810643
[PubMed - indexed for MEDLINE]
Free Article
16.

Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.

Gialeli Ch, Kletsas D, Mavroudis D, Kalofonos HP, Tzanakakis GN, Karamanos NK.

Curr Med Chem. 2009;16(29):3797-804. Review.

PMID:
19747140
[PubMed - indexed for MEDLINE]
17.

Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence.

Quatrale AE, Petriella D, Porcelli L, Tommasi S, Silvestris N, Colucci G, Angelo A, Azzariti A.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1973-85. Review.

PMID:
21196277
[PubMed - indexed for MEDLINE]
18.

Receptor tyrosine kinases and targeted cancer therapeutics.

Takeuchi K, Ito F.

Biol Pharm Bull. 2011;34(12):1774-80. Review.

PMID:
22130229
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

Targeting HER1/EGFR: a molecular approach to cancer therapy.

Arteaga C.

Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14. Review.

PMID:
12840796
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk